Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| MedCapital | Healthcare Services | 30.4% | 90th pct | 268 |
| Medison Holding | Healthcare Services | 12.8% | 57th pct | 268 |
| Med Investment | Healthcare Services | 6.1% | 38th pct | 268 |
| Reimani | Healthcare Services | -12.8% | 12th pct | 268 |
| Adiktologiis Regionalur… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Med Investment | Reimani | Medison Holding | MedCapital | Adiktologiis Regionalur… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 100.0% | 29.0% | 100.0% | 93.4% | — |
| EBITDA Margin | 6.1% | -12.8% | 12.8% | 30.4% | — |
| EBITDAR | 3,037 | -1,475 | 2,350 | 2,934 | — |
| EBITDAR Margin | 21.5% | -12.8% | 20.5% | 30.4% | — |
| EBIT Margin | 2.7% | -14.6% | 10.5% | 20.8% | — |
| Net Profit Margin | 5.3% | -15.1% | -1.9% | 21.4% | — |
| Operating Expense % of Sales | 93.9% | 41.8% | 87.2% | 63.0% | — |
| Returns | |||||
| Return on Assets (ROA) | 8.9% | -27.6% | -1.4% | 12.0% | — |
| Return on Equity (ROE) | N/A | N/A | -13.9% | 14.1% | — |
| ROIC [EBIT / Invested Capital] | |||||
| N/A |
| -49.4% |
| 8.5% |
| 13.7% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 4.1% | 173.5% | 81.9% | 0.0% | — |
| Debt-to-Equity | -0.19x | -1.50x | 8.27x | 0.00x | — |
| Debt-to-EBITDA | 0.41x | N/A | 8.78x | 0.00x | — |
| Equity-to-Assets | -22.3% | -116.0% | 9.9% | 85.2% | — |
| Net Debt | 342 | 10,712 | 12,620 | -24 | — |
| Cash & Equivalents | 11 | 222 | 313 | 24 | — |
| Total Debt | 353 | 10,934 | 12,933 | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.45x | 0.90x | 0.70x | 0.49x | — |
| Quick Ratio | 0.45x | 0.90x | 0.70x | 0.45x | — |
| Cash Ratio | 0.00x | 0.07x | 0.14x | 0.01x | — |
| Total Current Assets | 2,396 | 2,915 | 1,593 | 1,252 | — |
| Total Current Liabilities | 5,377 | 3,240 | 2,278 | 2,544 | — |
| Inventory | N/A | N/A | N/A | 104 | — |
| Trade Receivables | 2,086 | 728 | 995 | 1,124 | — |
| Trade Payables | 5,377 | 1,196 | 844 | 2,544 | — |
| Net Working Capital | -2,981 | -324 | -685 | -1,292 | — |
| Net Working Capital % of Revenue | -21.1% | -2.8% | -6.0% | -13.4% | — |
| Trade Working Capital | -3,291 | -468 | 150 | -1,316 | — |
| Trade Working Capital % of Revenue | -23.3% | -4.1% | 1.3% | -13.7% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | 6.12x | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | 59.6 | — |
| Receivables Turnover | 6.78x | 15.82x | 11.54x | 8.58x | — |
| Days Sales Outstanding (DSO) | 53.8 | 23.1 | 31.6 | 42.5 | — |
| Payables Turnover | N/A | 6.84x | N/A | 0.25x | — |
| Days Payable Outstanding (DPO) | N/A | 53.4 | N/A | 1464.6 | — |
| Cash Conversion Cycle | 53.8 days | -30.3 days | 31.6 days | -1362.4 days | — |
| Asset Turnover | 1.66x | 1.83x | 0.73x | 0.56x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 2 | 579 | N/A | 3,605 | — |
| Free Cash Flow (OCF − Capex proxy) | 2 | 87 | N/A | -306 | — |
| Cash Conversion (OCF / EBITDA) | 0.3% | N/A | N/A | 122.9% | — |
| Dividends Declared | N/A | N/A | N/A | 3,000 | — |
| Dividend Payout Ratio | N/A | N/A | N/A | 145.4% | — |